DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  05/16 04:00:01 pm EDT
10.62 USD   +3.01%
05/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/04Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Deciphera to Cut Workforce by 35%; to Discontinue Rebastinib Program; to Extend Cash Runway into 2024

11/30/2021 | 09:00am EDT


© MT Newswires 2021
All news about DECIPHERA PHARMACEUTICALS, INC.
05/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
05/04Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Revenue $29.2M, vs. Street Est..
MT
05/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Loss $-0.80, vs. Street Est of..
MT
05/04Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
BU
05/02Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
AQ
05/02Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Con..
BU
04/29Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
BU
04/28DECIPHERA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 126 M - -
Net income 2022 -178 M - -
Net cash 2022 359 M - -
P/E ratio 2022 -3,98x
Yield 2022 -
Capitalization 727 M 727 M -
EV / Sales 2022 2,93x
EV / Sales 2023 2,78x
Nbr of Employees 280
Free-Float 74,8%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 10,62 $
Average target price 11,38 $
Spread / Average Target 7,11%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.8.70%727
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601